ABBOTT INDIA LIMITED
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Biological: adalimumabBiological: placebo
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 90
- Registration Number
- NCT00445939
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Biological: adalimumabOther: Placebo
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 82
- Registration Number
- NCT00445432
- Locations
- 🇯🇵
Site Ref # / Investigator 46969, Kagawa, Japan
🇯🇵Site Ref # / Investigator 46971, Fukuoka, Japan
🇯🇵Site Ref # / Investigator 46978, Aichi, Japan
Testosterone Treatment for Hypogonadal Men
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 274
- Registration Number
- NCT00433199
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention-Deficit/Hyperactivity DisorderADHD
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2010-11-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 243
- Registration Number
- NCT00429091
- Locations
- 🇺🇸
Site Reference ID/Investigator# 5964, Burlington, Vermont, United States
🇺🇸Site Reference ID/Investigator# 5960, Clementon, New Jersey, United States
🇺🇸Site Reference ID/Investigator# 5970, Troy, Michigan, United States
A Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers
- Conditions
- Drug Interactions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2007-10-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 25
- Registration Number
- NCT00429468
A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2008-05-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 127
- Registration Number
- NCT00427362
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
- Conditions
- Crohn's Disease
- Interventions
- Biological: adalimumab
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 304
- Registration Number
- NCT00427921
- Locations
- 🇺🇸
Global Medical Information - Abbott, Abbott Park, Illinois, United States
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
- Conditions
- Diabetic NephropathyChronic Kidney Disease
- Interventions
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 281
- Registration Number
- NCT00421733
- Locations
- 🇺🇸
Site Reference ID/Investigator# 856, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 7214, Omaha, Nebraska, United States
🇺🇸Site Reference ID/Investigator# 6626, Winston-Salem, North Carolina, United States
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1032
- Registration Number
- NCT00420927
- Locations
- 🇺🇸
Site Reference ID/Investigator# 4548, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 4538, Houston, Texas, United States
🇺🇸Site Reference ID/Investigator# 4605, Wichita, Kansas, United States
An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2011-04-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 156
- Registration Number
- NCT00412620
- Locations
- 🇲🇽
Site Reference ID/Investigator# 4305, Guadalajara, Mexico
🇲🇽Site Reference ID/Investigator# 4298, Monterrey, Mexico
🇺🇸Site Reference ID/Investigator# 4173, San Diego, California, United States